文献速递胸部肿瘤

ERBB2等位基因特异性调控EGFR L861Q的致癌功能

Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers.
PubMed 文献 · J Thorac Oncol · 2020-10-07

该研究通过临床与临床前数据表征EGFR L861Q突变肺腺癌。1367例患者中3.4%携带L861Q,23.4%合并外显子18突变。L861Q致癌活性依赖不对称二聚化,对EGFR特异性抑制剂敏感性低于L858R,但对泛ERBB抑制剂敏感性相似,且ERBB2磷酸化显著升高。

要点

  • EGFR L861Q在肺癌中占3.4%,常合并外显子18突变(23.4%)。
  • L861Q对EGFR特异性抑制剂敏感性低于L858R,但对泛ERBB抑制剂敏感。
  • ERBB2在L861Q驱动肿瘤发生中起重要作用,泛ERBB抑制剂可能更有效。

核心结论

  • ERBB2在EGFR L861Q驱动的肿瘤发生中发挥先前未被认识的作用,泛ERBB抑制剂可能比选择性EGFR酪氨酸激酶抑制剂更有效。

研究设计与样本

  • 回顾性分析EGFR突变肺癌患者的临床和基因组数据,并建立表达EGFR突变的细胞进行功能分析。

主要发现

  • 1367例肺癌患者中3.4%(47例)携带EGFR L861Q突变;L861Q患者中23.4%(11/47)合并外显子18突变(通常涉及G719)。
  • 表达L861Q的细胞对EGFR特异性抑制剂敏感性低于表达L858R的细胞,但对泛ERBB抑制剂敏感性相似。
  • 表达L861Q的细胞中ERBB2磷酸化显著高于表达L858R的细胞,共免疫沉淀显示EGFR与ERBB2相互作用增强。
  • 奥希替尼处理增强抗凋亡蛋白MCL1表达,敲低ERBB2抑制L861Q细胞中MCL1表达。
  • 与EGFR特异性抑制剂相比,泛ERBB抑制剂对表达复合L861Q/G719X突变的细胞具有更优的生长抑制效果。

临床怎么用

  • 对于EGFR L861Q突变肺癌患者,泛ERBB抑制剂可能优于选择性EGFR酪氨酸激酶抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Unlike common EGFR mutations, many less common EGFR mutations remain poorly characterized in terms of oncogenic function and drug sensitivity. Here, we characterize the subset of lung adenocarcinoma harboring EGFR L861Q through both preclinical and clinical investigations. METHODS: We reviewed clinical and genomic data from patients with EGFR-mutant lung cancer. We established cells expressing EGFR mutations and performed functional analysis of L861Q in comparison with common EGFR mutations. RESULTS: Among the patients with lung cancer, 3.4% (47 of 1367) possess an EGFR L861Q mutation. Of the patients with L861Q, 23.4% (11 of 47) had a concurrent exon 18 mutation (typically involving G719). In vitro studies revealed that the oncogenic activity of L861Q is dependent on asymmetric dimerization. Cells expressing L861Q were less sensitive to EGFR-specific inhibitors compared with cells expressing L858R but were similarly sensitive to pan-ERBB inhibitors. In cells expressing L861Q, ERBB2 phosphorylation was markedly higher compared with cells expressing L858R, and an enhanced interaction between EGFR and ERBB2 was observed in coimmunoprecipitation studies. In addition, treatment with osimertinib enhanced expression of the antiapoptotic protein MCL1, and knockdown of ERBB2 suppressed the expression of MCL1 in L861Q, raising the possibility of differential allele-specific cross-phosphorylation of ERBB2. Moreover, compared with EGFR-specific inhibitors, pan-ERBB inhibitors exerted superior growth inhibitory effects on cells expressing compound L861Q/G719X mutations. CONCLUSIONS: Our results suggest that ERBB2 plays a previously unrecognized role in EGFR L861Q-driven tumorigenesis, and pan-ERBB inhibitors are likely to be more effective than selective EGFR tyrosine kinase inhibitors in this setting.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Sato H, Offin M, Kubota D, et al. Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. J Thorac Oncol. 2020. PMID: 33038514. doi:10.1016/j.jtho.2020.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。